"rationale","uuid:ID","instanceType","versionIdentifier","id"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","d0c7ca8b-0167-4720-b7e2-265b844fddfb","StudyVersion","2","StudyVersion_1"
